**Overview**

Fostamatinib is a small molecule prodrug of a tyrosine kinase inhibitor that inhibits the spleen tyrosine kinase (Syk). The major active metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor and reduces antibody-mediated destruction of platelets.

**Coverage Guidelines**

Authorization may be granted for members who are currently receiving treatment with Tavalisse, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**Or**

Authorization may be granted when the following criteria are met:

1. Member is diagnosed with chronic immune thrombocytopenia (ITP)
2. Member is at least 18 years of age
3. Member meets one of the following:
   - platelet count < 30,000 cells/mcL
   - medical necessity for platelet elevation (upcoming surgery, peptic ulcer disease or condition that may predispose member to bleeding) **and**
4. Member has had an inadequate response or intolerance with corticosteroids or immunoglobulins or has not responded to a splenectomy **and**
5. Member has had an inadequate response to maximally dosed Promacta (eltrombopag)

**Continuation of Therapy**

Reauthorizations may be granted when clinical documentation is submitted showing improvement in the platelet count.

**Limitations**
1. Initial approvals will be granted for 6 months.
2. Reauthorizations will be granted for 12 months.
3. The following quantity limits apply:

<table>
<thead>
<tr>
<th>Product</th>
<th>Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tavalisse 100mg</td>
<td>60 tablets</td>
</tr>
<tr>
<td>Tavalisse 150mg</td>
<td>60 tablets</td>
</tr>
</tbody>
</table>

References

1. Tavalisse (fostamatinib) [prescribing information]. South San Francisco, CA: Rigel Pharmaceuticals, Inc; April 2018.
4. Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol 2018; 181:183
5. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2019

Review History
04/17/2019 – Reviewed
05/20/2020 – Reviewed and Updated May P&T; references and overview updated; QL added to criteria; added started and stabilized statement. Effective 8/1/20.

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.